Advancing the Science

Mayo Clinic Medical Science Blog – an eclectic collection of research- and research education-related stories: feature stories, mini news bites, learning opportunities, profiles and more from Mayo Clinic.

July 2, 2019

Research News Roundup-June 2019

By Elizabeth Zimmermann

The Mayo Clinic Research News Roundup includes brief summaries and links to research news releases from the past month. It also connects readers to related resources. Read on for more information from Mayo Clinic Research.

Sometimes a physician thinks the outcome of a patient's treatment is a great success. Sometimes that patient thinks it was a flop.

That disconnect may go unexpressed by patients or unrecognized by health care providers. Even if there is a "outcome satisfaction" survey, it may not collect the right information or the outcomes measured for patients and physicians may be different and thus not comparable.

Shawn O'Driscoll, M.D., a Mayo Clinic orthopedic surgeon, wanted to develop an assessment process that would be informative, reliable and flexible enough to use across medical specialties.

Read about his research in developing the Summary Outcome Determination Score.


Micronutrient deficiencies, including vitamins B12 and D, as well as folate, iron, zinc and copper, are common in adults at the time of diagnosis with celiac disease. These deficiencies should be addressed at that time, according to a study by Mayo Clinic researchers.

The retrospective study of 309 adults newly diagnosed with celiac disease at Mayo Clinic from 2000 to 2014 also found that low body weight and weight loss, which are commonly associated with celiac disease, were less common. Weight loss was seen in only 25.2% of patients, and the average body mass index was categorized as overweight. The study will appear in the July print issue of Mayo Clinic Proceedings.


Despite improvements in median and short-term survival rates for patients with glioblastoma, the most common brain tumor in adults, the percentage of patients achieving five-year survival remains low, according to new Mayo Clinic research.

A study published June 20 in Mayo Clinic Proceedings finds that little has changed in terms of five-year survival — only 5.5% of patients live for five years after diagnosis — and calls for more aggressive treatments to be considered for all glioblastoma patients.


A new study by Mayo Clinic researchers may have broad implications for treatment of patients with predominantly benign thyroid disease and newly treated hypothyroidism.

The study published in the Mayo Clinic Proceedings July print edition, looked at whether generic and brand-name levothyroxine therapy affected hospitalization for cardiovascular events for those patients who are more at risk of coronary heart disease and heart failure. Levothyroxine is the most prescribed medication in the U.S., with more than 23 million prescriptions written annually.


A Minnesota statewide bipartisan initiative is transforming health care from a focus on treating disease to one of tapping the body's ability to heal itself. Regenerative Medicine Minnesota is a legislative initiative aimed at improving health by advancing regenerative medicine in research, technology, education and patient care across the state.

The 2019 annual meeting was held June 17, in Rochester, and co-chairs Andre Terzic, M.D., Ph.D., director of the Mayo Clinic Center for Regenerative Medicine and Jakub Tolar, M.D., Ph.D., dean of the Medical School and vice president for Clinical Affairs at the University of Minnesota, highlighted six “firsts” in advancing regenerative medicine toward patient care.

Read about them in the news release.


A generous $32 million gift from the New York-based Anna-Maria and Stephen Kellen Foundation will enable Mayo Clinic to expand its research mission with the construction of a four-story, 64,000-square-foot research building in Rochester, Minn.

"We cannot overstate our gratitude to the Anna-Maria and Stephen Kellen Foundation," says Gianrico Farrugia, M.D., Mayo Clinic's president and CEO. "Research is critical to infusing new knowledge into patient care. It paves the way to solve serious or complex medical challenges for our patients at Mayo as well as patients around the world. This remarkable gift will allow us to meet a critical need for research space on our Rochester campus."


Discrimination and bias in health care were the subject of some of Mayo's studies.

Mayo Clinic Cancer Center has long had a strong presence at the American Society of Clinical Oncology's annual meeting - the largest gathering of its kind, and #ASCO19 was no exception. This linked blog post contains brief summaries of (and links to) the four Mayo news releases sent out from the 2019 ASCO Annual Meeting in Chicago.


###

Find out more:

STAY CONNECTED — Advancing the Science

  • If you enjoyed this article, you might want to subscribe for regular updates.
  • If you want to share this story with friends, social media links are at the top of the article.
  • And if you want to see other recent stories on the blog, the index page is a great place to start.

Tags: Andre Terzic, ASCO, brain cancer, brain tumor, breast cancer, cardiology, cardiovascular medicine, celiac disease, Center for Regenerative Medicine, Center for the Science of Health Care Delivery, education, Events, Findings, Gianrico Farrugia, Mayo Clinic Cancer Center, Mayo Clinic Proceedings, News, orthopedics, patient experience, patient reported outcomes, regenerative medicine, Regenerative Medicine Minnesota, research, Research News Roundup, thyroid disease

Please login or register to post a reply.
Contact Us · Privacy Policy